Localized Prostate Cancer
Multimodal AI model superior to standard for prediction of key prostate cancer endpoints
SAN FRANCISCO — Prognostic biomarkers trained and validated through multimodal deep learning identified clinically relevant outcomes of men with localized prostate cancer better than standard clinical and pathologic variables, according to study results.
Hypofractionated, conventional radiation therapy show similar long-term efficacy in prostate cancer
Moderate hypofractionated intensity-modulated radiation therapy produced long-term outcomes similar to those of conventionally fractionated IMRT among men with localized prostate cancer, according to a 10-year update of a randomized phase 3 trial.
Updates in triple-negative breast cancer, patient feedback guides prostate cancer treatment — top stories in hematology/oncology
Healio presented updates in research and treatment of triple-negative breast cancer, an aggressive subtype that accounts for approximately 15% of all breast cancer cases. It was the top story in hematology/oncology last week.
Patient-reported outcomes could help guide selection of treatment for localized prostate cancer
Patient-reported adverse effect profiles 5 years after contemporary treatment for localized prostate cancer could help inform treatment choices for this patient population, according to study results published in JAMA.
FDA committee votes against approval of Tookad for localized prostate cancer
An FDA advisory committee today voted 2-13 against recommending approval of padeliporfin di-potassium, a minimally invasive treatment for localized prostate cancer.